| Title: | MidregiOnal proatrial natriuretic peptide to guide Secondary Stroke prevention: The MOSES Study |
| Short summary: | The present trial is addressing the question if a biologically distinct subgroup of ischemic stroke patients without known atrial fibrillation at admission, selected by a cut-off level of MRproANP concentration, which represents a underlying increased risk of cardiac thrombogenicity, benefits from direct oral anticoagulation (DOAC) versus antiplatelets as preventive treatment. |
| Study design: | International, multicenter, randomized-controlled, two-arm, assessorblinded trial |
| Status: | ongoing |
| PI or Local PI: | Prof. Gian Marco De Marchis |
| Link: | https://www.kssg.ch/system/files/media_document/2022-01/MOSES%20Studie_Internet.pdf |
